Cholesterol

Cholesterol

SCHEMBL892123

CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C.CCCCCCCCCCCCCCCCCCCCCC(=O)O

nearest known ligand 0.79

Full drug profile on Sugi Atlas →

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ OSBP P22059 3/20 0.79
▸ RORC P51449 2/20 0.79
▸ USP2 O75604 1/20 0.79
▸ LMNA P02545 1/20 0.79
▸ ABCB1 P08183 1/20 0.79
▸ OSBP2 Q969R2 1/20 0.79
▸ CYP46A1 Q9Y6A2 1/20 0.79
▸ NR1H3 Q13133 6/20 0.77
▸ EPHA2 P29317 1/20 0.77
▸ GRIN1 Q05586 1/20 0.68
▸ GRIN2A Q12879 1/20 0.68
▸ NPC1L1 Q9UHC9 2/20 0.67
▸ POLA1 P09884 1/20 0.67
▸ DHCR24 Q15392 1/20 0.66

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Cholesterol SCHEMBL970382 1.00 OSBP (0.79) OSBPRORCUSP2LMNAABCB1
Cholesterol SCHEMBL9566174 1.00 OSBP (0.79) OSBPRORCUSP2LMNAABCB1
Cholesterol SCHEMBL7736671 1.00 OSBP (0.79) OSBPRORCUSP2LMNAABCB1
Cholesterol SCHEMBL161748 1.00 OSBP (0.79) OSBPRORCUSP2LMNAABCB1
Cholesterol SCHEMBL2195602 1.00 OSBP (0.79) OSBPRORCUSP2LMNAABCB1
Cholesterol SCHEMBL10933840 1.00 OSBP (0.79) OSBPRORCUSP2LMNAABCB1
Cholesterol SCHEMBL25174230 1.00 OSBP (0.79) OSBPRORCUSP2LMNAABCB1
Cholesterol SCHEMBL16415838 1.00 OSBP (0.79) OSBPRORCUSP2LMNAABCB1
Cholesterol SCHEMBL10883099 1.00 OSBP (0.79) OSBPRORCUSP2LMNAABCB1
Cholesterol SCHEMBL22749559 1.00 OSBP (0.79) OSBPRORCUSP2LMNAABCB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 120 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12233034-B2 Formulations for epidermal repair CLARIDEI LABORATORIES, INC. (US) 2025-02-25 — — US claimed
US-20220031640-A1 FORMULATIONS FOR EPIDURAL REPAIR CLARIDEI LABORATORIES, INC. 2022-02-03 — — US claimed
CN-113679689-A Compositions and methods for nanoparticle lyophilisate form 日东电工株式会社 2021-11-23 — — CN claimed
US-11135184-B2 Formulations for epidermal repair CLARIDEI LABORATORIES, INC. (US) 2021-10-05 — — US claimed
CN-112430485-A Additive suitable for liquid fuel 王趁义 2021-03-02 — — CN claimed
US-20180289642-A1 FORMULATIONS FOR EPIDERMAL REPAIR CLARIDEI LABORATORIES, INC. 2018-10-11 — — US claimed
CN-108024957-A Compositions and methods for nanoparticle lyophilisate form 日东电工株式会社 2018-05-11 — — CN claimed
CN-105792810-A Formula for epidermis repair 绮丽儿·李·艾柏汀 2016-07-20 — — CN claimed
US-20160184245-A1 FORMULATIONS FOR EPIDERMAL REPAIR CLARIDEI LABORATORIES, INC. 2016-06-30 — — US claimed
EP-3024438-A1 FORMULATIONS FOR EPIDERMAL REPAIR Eberting, Cheryl Lee (US) 2016-06-01 — — EP claimed
CN-104672311-A Lipopeptides for delivery of nucleic acids MARINA BIOTECH INC 2015-06-03 — — CN claimed
WO-2015013634-A1 FORMULATIONS FOR EPIDERMAL REPAIR EBERTING CHERYL LEE (US) 2015-01-29 — — WO claimed
CN-101939027-B Lipopeptides for delivery of nucleic acids MDRNA INC 2014-07-30 — — CN claimed
CN-101939027-A Lipopeptides for delivery of nucleic acids MDRNA INC 2011-01-05 — — CN claimed
CN-118339237-B Reversible thermochromic microcapsule pigments 株式会社百乐 2026-05-12 — — CN disclosed
US-12233034-B2 Formulations for epidermal repair CLARIDEI LABORATORIES, INC. (US) 2025-02-25 — — US disclosed
CN-113767159-B Reversible thermochromic microcapsule pigment 百乐墨水株式会社 2024-12-06 — — CN disclosed
EP-0763569-B1 metal complex methin dye KONISHIROKU PHOTO IND (JP) 2000-11-22 — — EP disclosed
US-5892033-A THERMAL TRANSFER RECORDING; ELECTROSTATIC IMAGING KONICA CORPORATION (JP) 1999-04-06 — — US disclosed
EP-0763569-A1 metal complex methin dye KONICA CORPORATION (JP) 1997-03-19 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12233034-B2 Formulations for epidermal repair KRT18, CUTA, DSG1 OSBP 857/4885RORC 356/4885USP2 1927/4885
US-20180289642-A1 FORMULATIONS FOR EPIDERMAL REPAIR KRT18, CUTA, DSG1 OSBP 975/4885RORC 377/4885USP2 1921/4885
US-20160184245-A1 FORMULATIONS FOR EPIDERMAL REPAIR KRT18, CUTA, DSG1 OSBP 857/4885RORC 356/4885USP2 1927/4885
US-20220031640-A1 FORMULATIONS FOR EPIDURAL REPAIR CUTA, EPHB1, EPHB2 OSBP 780/4885RORC 281/4885USP2 2428/4885
US-11135184-B2 Formulations for epidermal repair KRT18, CUTA, DSG1 OSBP 857/4885RORC 356/4885USP2 1927/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback